Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Parasitic organism or component thereof or substance...
Patent
1994-09-21
1997-10-07
Sidberry, Hazel F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Parasitic organism or component thereof or substance...
4241841, 4241851, 530324, 530325, 530326, 530327, 530300, A61K 39008, A61K 3800, A61K 3804, C07K 1444
Patent
active
056745036
ABSTRACT:
The present invention provides immunogens suitable for vaccination against leishmaniasis.
REFERENCES:
Medina-Acoster Mol. & Bioch. Paras 37:263-274 1989.
Russell et al The J. of Imm 140:1274-1279 Feb. 1988.
Button et al the J. of Exp Med. "The Molecular Cloning of the Major Surface Antigen of Leishmania." vol. 167:724-729 1988.
Margalit et al The Journ of Imm. 138:2213-2229, 1987 Prediction of Immunodominant Helper T Cell Antigenic Sites From the Primary Sequence.
Brot et al Archives of Biochem & Biophysics, 223:271-281 1983, "Biochemistry & Physiological Role of Melhroune Sulfoxide Residues in Proteins".
Rothbard and Taylor, EMBO Journal 7:93-100 1988, "A Sequence Pattern Common to T-Cell Epitopes".
Russell et al, The J. of Imm. 140:1274-1279, 1985, Effective Immunization Against Cutaneous Leishmaniasis in the Defined Membrane Antigen Reconstituted into Liposomes.
Modabben Parasitology 98:S49-S60, 1989 Expreiences with Vaccines Against Cutaneous Leishmaniasis of Mice & Men.
Clark The Journ. of Immun. 2725-2725 vol. 129, 1982 "Chemotactic Factors Trigger Their Own Oxidative Inactivation by Human Neutrophils".
Clark et al The Journ of Imm. 126:1507-1513, 1982 Chemotactic Factor Inactivation by Stimulated Human Neutrophils Mediated by Myeloperoxidase-Catalyzed Melhionine Oxidation.
Stryer, Biochemistry p. 15, 2nd Ed copy 1975, 1981.
Kumar et al, PNAS 87:1337-1341 1990. Amino Acid Variations at a Single Residue in an Autoimmune Peptide Profoundly Affect its Properties: T-Cell Activator, Major Histocompatibility Complex Binding & Ability to Block Experim.
Chaudhuri et al., "Surface Acid Proteinase (gp63) of Leishmania mexicana," J. Biol. Chem. 264(13):7483-7489, 1989.
Hill et al., "Elimination of CD4 .sup.+ Suppressor T Cells From Susceptible BALB/C Mice Releases CD8.sup.+ T Lymphocytes to Mediate Protective Immunity Against Leishmania," J. Exp. Med. 169:1819-1827, 1989.
Reiner et al., "Genetic Heterogeneity in Peruvian Leishmania Isolates," Am. J. Trop. Med. Hyg. 41(4):416-421, 1989.
Farrell et al., "A Role for LYT-2 .sup.+ T Cells in Resistance to Cutaneous Leishmaniasis in Immunized Mice," J. Immunology 142(6):2052-2056, 1989.
Liew et al., "Prophylactic Immunization Against Experimental Leishmaniasis: VI. Comparison of Protective and Disease-Promoting T Cells," J. Immunology 139(9):3112-3117, 1987.
Mitchell and Handman, "The Glyconjugate Derived From a Leishmania major Receptor for Macrophages Is a Suppressogenic, Disease-Promoting Antigen in Murine Cutaneous Leishmaniasis," Parasite Immunology 8:255-263, 1986.
Handman and Mitchell, "Immunization with Leishmania Receptor for Macrophages Protects Mice Against Cutaneous Leishmaniasis," Proc. Natl. Acad. Sci. USA 82:5910-5914, 1985.
Liew et al., "Prophylactic Immunization Against Experimental Leishmaniasis: IV. Subcutaneous Immunization Prevents the Induction of Protective Immunity Against Fatal Leishmania major Infection," J. Immunology 135(3):2095-2101, 1985.
Liew et al., "Prophylactic Immunization Against Experimental Leishmaniasis: V. Mechanism of the Anti-Protective Blocking Effect Induced by Subcutaneous Immunization Against Leishmania major Infection," J. Immunology 135(3):2102-2107, 1985.
Dhaliwal et al., "Specific Suppressor T Cells for Delayed-Type Hypersensitivity in Susceptible Mice Immunized Against Cutaneous Leishmaniasis," Infection & Immunity 49(2):417-423, 1985.
Liew et al., "Prophylactic Immunization Against Experimental Leishmaniasis: III. Protection Against Fatal Leishmania tropica Infection Induced by Irradiated Promastigotes Involves LYT-1.sup.+ 2.sup.- T Cells that Do Not Mediate Cutaneous DTH," J. Immunology 132(1):456-461, 1984.
Koufman et al., "Observations on Immunization Against Cutaneous Leishmaniasis in Israel," Israel J. Med. Sci. 14(2):218-222, 1978.
McMaster et al., "Molecular Genetics of the Major Glycoprotein and Repetitive Antigens of Leishmania," Parasites: Molecular Biology, Drug and Vaccine Design O 013, p. 69.
Button et al., "Expression in Escherichia coli of Genes Encoding the Major Surface Glycoprotein From Leishmania," Parasites: Molecular Biology, Drug and Vaccine Design O 408, p. 99.
Webb et al., "Comparison of the Genomic DNA Sequence Enconding the Cell Surface Glycoprotein Gp63 of Leishmania major and L. donovani," Parasites: Molecular Biology, Drug and Vaccine Design O 488, p. 126.
Titus et al., "Induction of Resistance to Experimental Cutaneous Leishmaniasis in Genetically-Susceptible BALB/C Mice by Immunization with Chemically-Mutagenized Non-Infective Clones of Leishmania major," Microbial-Immune Response Interactions III (3436-3441), 3436, A887.
Sidberry Hazel F.
University of Victoria
LandOfFree
Peptides capable of eliciting an immune response to leishmaniasi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides capable of eliciting an immune response to leishmaniasi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides capable of eliciting an immune response to leishmaniasi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2354593